Figure 3From: RPS2: a novel therapeutic target in prostate cancerImmunolabeling of PC-3ML, CPTX-1532 and NPTX-1532 cells with RPS2 antibodies following treatment with 4 ug/ml DNAZYM-1P or scrambled oligonucleotide for 0, 4 and 24 hr. Cells were labeled with RPS2 P1 antibody (1:200 dil.) and Alexoflour secondary antibodies counterstained with DAPI. Cells were at ~70% confluence at the time treatment was initiated.Back to article page